Literature DB >> 6933807

Antihypertensive treatment inhibiting the progression of diabetic nephropathy.

C E Mogensen.   

Abstract

In 6 male insulin-dependent proteinuric long-term diabetics aged 26-35 years the rate of progression of nephropathy was followed for an initial control period of 2.0 years and subsequently for 4.1 years during antihypertensive therapy with a beta-receptor blocker combined with Hydralazine and Furosemide. GFR and urinary albumin excretion was measured 3-4 times before and 9-14 times during treatment. Systolic blood pressure was reduced significantly from 162 +/- 14 (SD) mm Hg before treatment to 146 +/- 9 (SD) as a mean during the whole treatment period (2p = 0.002). Diastolic pressure was also reduced significantly, from 103 +/- 9 (SD) mm Hg to 95 +/- 8 (SD), (2p = 0.025). After 49 days of treatment there was a significant fall in albumin clearance as a per cent of GFR from 0.243 +/- 0.28 (SD) to 0.170 +/- 0.20 (SD), (2p < 0.001 for percentage change) with no change in GFR. In five patients the fall rate of GFR was in the initial control period 1.24 ml/min/month +/- 0.8 (SD). In the period when antihypertensive therapy was given it was reduced to 0.45 ml/min/month +/- 0.5 (SD) (2p = 0.037). In the 6th patient there was no decline in GFR neither before, nor during treatment. Before treatment there was a mean yearly percentage increase in albumin excretion of 107 per cent. During treatment this yearly increase was reduced to--7 per cent (2p = 0.002 for differences in slope). The results indicate that the state of renal insufficiency in diabetic patients with nephropathy and moderately increased blood pressure can be postponed by antihypertensive treatment. Other trials should be carried out to define the optimal scheme of treatment.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6933807

Source DB:  PubMed          Journal:  Acta Endocrinol Suppl (Copenh)        ISSN: 0300-9750


  9 in total

Review 1.  Costs of insulin-dependent diabetes mellitus.

Authors:  T T Simell; H Sintonen; J Hahl; O G Simell
Journal:  Pharmacoeconomics       Date:  1996-01       Impact factor: 4.981

Review 2.  Functional and morphological renal manifestations in diabetes mellitus.

Authors:  C E Mogensen; M W Steffes; T Deckert; J S Christiansen
Journal:  Diabetologia       Date:  1981-08       Impact factor: 10.122

3.  Genesis and evolution of diabetic nephropathy.

Authors:  H Keen; G C Viberti
Journal:  J Clin Pathol       Date:  1981-11       Impact factor: 3.411

4.  Further views on the basement membrane controversy.

Authors:  L O Simpson
Journal:  Diabetologia       Date:  1981-12       Impact factor: 10.122

5.  Are the 'second generation' oral hypoglycemic agents really different?

Authors:  E F Pfeiffer
Journal:  Acta Diabetol Lat       Date:  1984 Jan-Mar

6.  [Early detection of diabetic nephropathy: serum beta 2-microglobulin].

Authors:  F D Goebel; T Schmeidl; H S Füessl; S Vogel
Journal:  Klin Wochenschr       Date:  1983-12-01

Review 7.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

Review 8.  The natural history of diabetic nephropathy in type I diabetes and the role of metabolic control in its prevention, reversibility and clinical course.

Authors:  B L Wajchenberg; E Sabbaga; J A Fonseca
Journal:  Acta Diabetol Lat       Date:  1983 Jan-Mar

9.  The pathophysiology of experimental insulin-deficient diabetes in the monkey. Implications for pancreatic transplantation.

Authors:  O Jonasson; C W Jones; A Bauman; E John; J Manaligod; M O Tso
Journal:  Ann Surg       Date:  1985-01       Impact factor: 12.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.